[A25-38] Atogepant (migraine) – Benefit assessment according to §35a Social Code Book V
Last updated 02.06.2025
Project no.:
A25-38
Commission:
Commission awarded on 28.02.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
Adults who have at least 4 migraine days per month
Result of dossier assessment:
- Patients who are candidates for conventional migraine prophylaxis: added benefit not proven
- Patients who do not respond to any of the following drug treatments/drug classes, for whom they are unsuitable, or who do not tolerate them: metoprolol, propranolol, flunarizine, amitriptyline, clostridium botulinum toxin type A: added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-38